An overview of nonclinical study and evaluation of diagnostic radiopharmaceuticals approved for marketing in the United States in the last two decadesLI Ai-fang, GUANG Hong-mei, WANG Qing-li865-870
Consideration on key points of clinical trials for advanced renal cell carcinoma in ChinaXIA Lin, SONG Yuan-yuan, HAO Rui-min, YANG Zhi-min871-875
Research progress in viral clearance validation strategy of recombinant biological productsSAI Wen-bo, YU Peng-li, LI Xiao-jing, WEI Wei876-879
Introduction and interpretation of USP〈1207〉package integrity evaluation for sterile productsGUO Di-liang, DONG Wu-jun, MA Jun-wei, WANG Lu, LI Zhong-jie880-885
Considerations for the bioequivalence study of oral antitumor genericsLIU Fei-fei, YANG Jin-bo, WANG Yu-zhu886-892
Overview of the nonclinical study and evaluation of therapeutic drugs for transthyretin amyloidosis diseaseLI Ai-fang, GUANG Hong-mei, WANG Qing-li893-897
Investigation and considerations about clinical position and effect evaluation system and criterion suited for traditional Chinese medicineSONG Cai-mei, LIU Bing-lin, XUE Fei-ran, HAN Ling898-901
Some opinions about analytical method validation in drug research and developmentLI Fei, LI Yun902-904
Global approved new drugs in 2020:retrospect and prospectWU Meng, SUN You-song, CHEN Qian, YANG Zhen-zheng, ZHENG Xiao-nan905-914
Analysis of technological innovation of traditional Chinese medicine in universities of China from the perspective of patentSUN Chuan-liang, SUN Li-bing915-920